Mandatory notification of trade

Moss, 5 May 2023 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction has been completed by a close associate of a primary insider in Gentian: Holta Invest AS ("Holta"), a close associate of primary insider Espen Tidemann Jørgensen, board member, is in the process of simplifying its group structure. The re-organization will result in its ownership in Gentian, currently owned indirectly through Holta Life Sciences AS and Holta Horisont AS, will be owned directly by Holta. Holta's total ownership in Gentian will remain unchanged as a result of the re-organization. Firstly, Holta Horisont AS has today sold all its 13,800 shares in Gentian to Holta Invest AS at a share price of NOK 47.50 per share. Secondly, Holta Life Sciences AS has today sold all its 1,214,702 shares in Gentian to Holta Invest AS at a share price of NOK 47.50 per share. Following the above transactions Holta Horisont AS and Holta Life Sciences AS hold no shares in Gentian. Holta's total ownership of 1,228,702 shares (7,97%) in Gentian has not changed as result of the above transactions. IR Contact: Njaal Kind, Group CFO, njaal.kind@gentian.no, +47 91 90 65 25 Please refer to the attached notification of trading for further details. This information is subject to the disclosure requirements in the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.